Craft
Kuros Biosciences

Kuros Biosciences

Revenue

CHF13.8 M

FY, 2021

Market Capitalization

CHF53.1 M

2023-01-27

Kuros Biosciences Summary

Company summary

Overview
Kuros Biosciences engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The Сompany's synthetic orthobiologics pipeline products comprise MagnetOs Granules EU and MagnetOs Putty EU for the treatment of orthopedics, spinal, and dental problems; and MagnetOs Granules US and MagnetOs Putty US for the treatment of spinal fusion.
Type
Public
Status
Active
Founded
2000
HQ
Schlieren, CH | view all locations
Website
https://kurosbio.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Michael Grau

    Michael Grau, Chief Financial Officer

    • Joost de Bruijn

      Joost de Bruijn, Chief Executive Officer, Director

      • Alistair Irvine

        Alistair Irvine, Chief Business Officer

        • Phillippe Saudan

          Phillippe Saudan, Chief Development Officer

          LocationsView all

          3 locations detected

          • Schlieren HQ

            Switzerland

            25 Wagistrasse

          • Burlington, MA

            United States

            111 S Bedford St #108

          • Bilthoven, UT

            Netherlands

            Professor Bronkhorstlaan 10, G 48

          Kuros Biosciences Financials

          Summary financials

          Revenue (H1, 2022)
          CHF10.4M
          Gross profit (H1, 2022)
          CHF10.1M
          Net income (H1, 2022)
          (CHF3.7M)
          Cash (H1, 2022)
          CHF21.6M
          EBIT (H1, 2022)
          (CHF2.4M)
          Enterprise value
          $41.9M

          Footer menu